FANCF methylation contributes to chemoselectivity in ovarian cancer.
暂无分享，去创建一个
[1] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[2] Rachel Jones,et al. Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.
[3] Joanna R. Morris,et al. BRCA1 methylation: a significant role in tumour development? , 2002, Seminars in cancer biology.
[4] Hans Joenje,et al. Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.
[5] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[6] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[7] Ashok R Venkitaraman,et al. Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.
[8] R. Berkowitz,et al. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. , 1997, Cancer research.
[9] A. D’Andrea,et al. The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.
[10] M. Stratton,et al. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. , 1997, British Journal of Cancer.